Low heart-type fatty acid binding protein level during aging may protect down syndrome people against atherosclerosis

Immunity & Ageing

Massimiliano Marco Corsi Romanelli¹  Elena Dozio²  Giada Dogliotti²  Elena Vianello² 

[1] U.O.C. di Patologia Clinica, Dipartimento dei Servizi Sanitari di Diagnosi e Cura – Medicina di Laboratorio, IRCCS Policlinico San Donato, Piazza E. Malan, 20097 San Donato Milanese, Milan, Italy;Dipartimento di Scienze Biomediche per la Salute, Cattedra di Patologia Clinica, Università degli Studi di Milano, Via Mangiagalli 31, Milan, 20133, Italy

关键词: Heart-type fatty acid binding protein;    Down syndrome;    Atherosclerosis;    Aging;   

Others  :  815154
DOI  :  10.1186/1742-4933-10-2

 received in 2012-10-30, accepted in 2013-01-17,  发布年份 2013

【 摘 要 】

Background

Aging is considered an important independent risk factor for atherosclerosis. Down syndrome people (DS) display an accelerated aging process compared to healthy subjects, anyway they are relatively resistant to developing atherosclerosis. The mechanisms involved in such protective effect are not well known. Since heart-type fatty acid binding protein (H-FABP) is a protein involved in the transport of fatty acids and it has been recently correlated with the presence of atherosclerosis, we aimed to measure H-FABP level both in DS and in healthy subjects during aging to evaluate the association between this molecule, aging and atherosclerosis.

Findings

We quantified plasmatic H-FABP level in three groups of male DS and age-matched healthy subjects (children, age 2–14 years; adults, age 20–50 years; elderly, > 60 years) using a biochip array analyzer. We observed that aging is associated with increased H-FABP level in healthy subjects but not in DS which display both the same protein level in the different ages of life and have also lower level compared to their age-matched healthy subjects.

Conclusion

Reduced H-FABP level during aging in DS may play a protective role against atherosclerosis. The potential involvement of H-FABP in the relationship between aging, atherosclerosis and development of coronary artery disease needs further investigations.

【 授权许可】

   
2013 Vianello et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]More KJ, Tabas I: Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.
• [2]Wang JC, Bennet M: Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 2012, 111:245-259.
• [3]Fournier NC, Richard MA: Role of fatty acid-binding protein in cardiac fatty acid oxidation. Mol Cell Biochem 1990, 98:149-159.
• [4]Nagahara D, Nagahara T, Hashimoto A, Takahashi T, Kyuma M, Hase M, Tsuchihashi K, Shimamoto K: Early positive biomarker in relation to myocardial necrosis and impaired fatty acid metabolism in patients presenting with acute chest pain at an emergency room. Cir J 2006, 70:419-425.
• [5]Basak K, Ozbek M, Bozkurt NC, Ginis Z, Gungunes A, Unsal IO, Cakal E, Delibasi T: Heart-type fatty acid binding protein (H-FABP): relationship with arterial intima-media thickness and role as diagnostic marker for atherosclerosis in patients with impaired glucose metabolism. Cardiovasc Diabetol 2011, 10:37. BioMed Central Full Text
• [6]Murdoch JC, Rodger JC, Rao SS: Down’s syndrome: an atheroma free model ? Br Med J 1977, 2:226-228.
• [7]Patterson D: Molecular genetic analysis of down syndrome. Human Genetic 2009, 126:195-214.
• [8]Ylä-Herttuala S, Luoma J, Nikkari T, Kivimaki T: Down’s syndrome and atherosclerosis. Atherosclerosis 1989, 76:269-272.
• [9]Niizeki T, Takeishi Y, Takabatake N, Shibata Y, Konta T, Kato T, Kawata S, Kubota I: Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: effects of age, gender, and physiologic characteristics. Circ J 2007, 71:1452-1457.
• [10]Dogliotti G, Galliera E, Licastro F, Corsi MM: Age-related changes in plasma levels of BDNF in Down syndrome patients. Immun Ageing 2010, 25:7.
• [11]Corsi MM, Dogliotti G, Pedroni F, Galliera E, Malavazos AE, Villa R, Chiappelli M, Licastro F: Adipocytokines in Down’s syndrome, an atheroma-free model: Role of adiponectin. Arch Gerontol Geriatr 2009, 48:106-109.